To treat or not to treat cancer patients with chemotherapy at the end of life?

Prescrire International

Volumn 20, Issue 117, 2011, Pages 152-153

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; MONOCLONAL ANTIBODY;

ASCITES; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CAUSE OF DEATH; DRUG FATALITY; DRUG SAFETY; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PLEURA EFFUSION; SHORT SURVEY; SOLID TUMOR; TERMINAL CARE;

ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; HUMANS; NEOPLASMS; PALLIATIVE CARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957769630     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (4)

1. Prescrire Rédaction "Enrichir sa panoplie thérapeutique. Bilan de l'année 2008" Rev Prescrire 2009; 29 (303): 27-30.
2. Prescrire Rédaction "Mieux soigner les malades en fin de vie - Deuxième partie: il n'y a pas que la douleur" Rev Prescrire 1997; 17 (179): 829-839.
3. Mort D et al. "For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy" National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 2008: 149 pages.
4. HAS "La revue de mortalité et de morbidité (RMM): une démarche d'amélioration de la qualité et de la sécurité des soins" 10 juin 2009. www.has-sante.fr accessed 15 September 2010.